Published in
Oxford University Press (OUP), Clinical Infectious Diseases, 3(54), p. 414-423
DOI: 10.1093/cid/cir799
Links
- ORCID
- Oxford University Press (OUP) | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [europepmc.org] | PDF
- [www.researchgate.net] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [citeseerx.ist.psu.edu] | PDF
Tools
Interactions Between Buprenorphine and the Protease Inhibitors Darunavir-Ritonavir and Fosamprenavir-Ritonavir
Journal article published in 2011 by
Valerie A. Gruber,
Petrie M. Rainey,
David E. Moody,
Gene D. Morse,
Qing Ma 
,
Qing,
Sudha Prathikanti,
Patricia A. Pade,
Anika A. H. Alvanzo,
Elinore F. McCance-Katz
,
Qing,
Sudha Prathikanti,
Patricia A. Pade,
Anika A. H. Alvanzo,
Elinore F. McCance-Katz
This paper is made freely available by the publisher.
Full text: Download
Published version:
archiving forbidden
Data provided by 
Abstract
In adults receiving buprenorphine-naloxone maintenance, buprenorphine pharmacokinetics were not changed significantly by 15-day coadministration of darunavir-ritonavir or fosamprenavir-ritonavir. The pharmacokinetics of the protease inhibitors did not differ from those in matched controls receiving only the protease inhibitors.